The stock's rise snapped a four-day losing streak.
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...
BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback